Primary biliary cholangitis

This Phase 3 trial tests elafibranor, a daily pill, against a placebo in 276 adults with primary biliary cholangitis (PBC) and cirrhosis. The goal is to see if elafibranor can prevent disease worsening, such as liver failure or death, over up to 3.5 years. Researchers will also m…

This study follows about 424 people with primary biliary cholangitis (PBC) who are taking elafibranor as part of their normal care. Researchers will track how well the drug controls liver damage and symptoms like itching over 5 years. The goal is to see if elafibranor works safel…

This Phase 3 trial tests whether seladelpar, a daily pill, can improve outcomes for people with primary biliary cholangitis (PBC) who also have compensated cirrhosis. About 318 adults will receive either seladelpar or a placebo for up to 36 months. The study tracks serious events…

This study tests whether a machine that keeps donated livers working outside the body can help doctors safely use livers that were previously considered too risky for transplant. About 186 adults on the liver transplant waiting list will be randomly assigned to either receive a s…

This study tests whether a daily nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein can improve liver function and quality of life in adults with liver disease from chronic hepatitis C. Over 12 weeks, 26 participants will take either the s…

This early-stage trial is testing whether a combination of two natural substances, deoxycytidine and deoxythymidine, is safe for people with telomere biology disorders. These rare genetic conditions cause premature aging, bone marrow failure, and lung scarring. Up to 36 participa…

This study is for adults with primary biliary cholangitis (a chronic liver disease) who also have cirrhosis and did not respond well to the usual treatment, ursodeoxycholic acid. Researchers want to see if adding fenofibrate to their treatment can improve liver health by normaliz…

This long-term study is testing whether adding fenofibrate to standard ursodeoxycholic acid is safe for people with primary biliary cholangitis (PBC), a rare liver disease. About 300 adults who have already completed a prior fenofibrate study will take the combination and be moni…

This study tests the long-term safety of combining fenofibrate with standard treatment (ursodeoxycholic acid) in 150 adults with primary biliary cholangitis, a chronic liver disease. Participants previously completed a related study and will take fenofibrate capsules daily. Resea…

This Phase 3 trial tests whether adding fenofibrate to standard ursodeoxycholic acid (UDCA) therapy improves liver health in people with primary biliary cholangitis (PBC) who do not respond well to UDCA alone. About 150 adults will receive either the combination or a placebo plus…

This study tests a new drug called CS0159 in 135 adults with primary biliary cholangitis (PBC), a chronic liver disease. Participants must have had an inadequate response or intolerance to the standard treatment UDCA. The trial compares CS0159 to a placebo over 52 weeks to see if…

This study tests whether fenofibrate, a drug used for high cholesterol, can improve liver function in adults with primary biliary cholangitis (PBC) who haven't been treated before. About 132 participants will take either fenofibrate or the standard drug UDCA for 12 months. The go…

This early-stage trial is testing whether giving a mix of healthy gut bacteria (from donors) to people hospitalized with serious liver disease is safe and tolerable. The study involves 24 adults with liver failure or cirrhosis who have low levels of certain gut metabolites. Resea…

This study aims to create a simple blood test to find liver cancer at an early, more treatable stage. Researchers will analyze genetic material in the blood of 600 adults, including those with liver cancer, chronic liver disease, and healthy volunteers. The goal is to improve ear…

This study tests a new endoscopic ultrasound method (EUS-SWQ) to measure liver stiffness and diagnose liver fibrosis (scarring) in people with chronic liver disease. Researchers will compare EUS-SWQ results with standard liver biopsy and FibroScan in 65 adults. The goal is to see…

This study is testing a new, non-invasive ultrasound device called the Hepatoscope to screen for liver scarring (fibrosis) and fatty liver in people at risk. Researchers will enroll 200 patients with risk factors like diabetes or elevated liver enzymes. Those with high stiffness …

This study looks for early signs of primary biliary cholangitis (PBC) in adults who have certain antibodies (AMA) but normal liver enzyme levels (ALP). Researchers will perform liver biopsies and special blood tests on 80 participants to find clues that could lead to earlier diag…

This study is testing whether special ultrasound scans can accurately detect liver damage in children without needing a needle biopsy. Researchers will compare these scans to standard biopsy results in 550 children with various liver conditions. If the scans prove reliable, they …

This study is testing a blood test called hepatomiR to see if it can predict when people with chronic liver disease will develop serious complications like fluid buildup in the belly, bleeding from the esophagus, or confusion from liver failure. Researchers will follow 156 outpat…

This study tests a drug called golexanolone in 84 people with primary biliary cholangitis (PBC) who suffer from significant fatigue and cognitive problems. Participants receive either the drug or a placebo for up to 28 days. The goal is to see if the drug is safe and can improve …

This study tests an experimental drug called volixibat for people with primary biliary cholangitis (PBC) who suffer from severe itching. The trial will involve 260 adults and compare volixibat against a placebo to see if it safely reduces itch severity and improves quality of lif…

This study tests whether a program combining exercise, nutritional advice, and psychological support can reduce fatigue in people with primary biliary cholangitis (PBC). 64 participants with moderate to severe fatigue will be randomly assigned to either the rehab program or stand…

This study at the National Institutes of Health is looking at 1,000 adults with known or suspected hormone gland (endocrine) disorders. The goal is to better understand these conditions and help train doctors. Participants may receive tests, treatments, or surgery as part of thei…

This study enrolls up to 15,000 children with known or suspected endocrine or metabolic disorders, along with their family members. Researchers will collect medical records, blood, saliva, and other samples to identify genetic changes linked to these conditions. The goal is to be…

This study looks at how the drug mirdametinib is absorbed and removed from the body in people with moderate or severe liver problems compared to those with normal liver function. It involves 32 adults and is for research only, not to treat any condition. The goal is to understand…

This study aims to collect medical data and biological samples (blood, urine, stool, and tissue) from up to 4,000 adults with known or suspected gastrointestinal diseases. Participants receive standard medical care at the NIH, and any extra samples or leftover tissue from procedu…

This early-stage study looks at how a new drug, INCB123667, behaves in the bodies of 16 adults with moderate or severe liver disease. Researchers will measure drug levels and watch for side effects. The goal is to gather safety information, not to treat the liver condition.

This early-stage study is testing how the drug BMS-986435 behaves in the body and whether it is safe for people with mild to moderate liver problems compared to those with healthy livers. 24 adults will receive a single dose, and researchers will measure drug levels and monitor f…

This early-phase study looks at how a single dose of the drug inavolisib behaves in people with moderate or severe liver impairment compared to healthy volunteers. Researchers will measure drug levels in the blood and check for side effects. The goal is to understand if liver pro…

This study looks at how a single dose of the experimental drug BI 1291583 behaves in the blood of people with and without liver problems. The drug is being developed for bronchiectasis, a chronic lung disease. About 32 adults aged 18–80 will take part, divided into groups based o…

This early-stage study is testing a single dose of the drug eloralintide in 36 people with different levels of liver function—from healthy to severely impaired. Researchers want to see how the body absorbs and processes the drug and whether it causes side effects. The goal is to …

This early-stage study looks at how the liver handles two experimental drugs, AZD9550 and AZD6234, in people with moderate to severe liver problems compared to healthy volunteers. About 28 adults will receive a single injection of one drug. The goal is to see if liver impairment …

This early-stage study by Pfizer looks at how different levels of liver function affect the processing of a new drug called PF-07328948. About 26 adults with and without liver impairment will take a single tablet and stay at the clinic for 6 days for monitoring and blood tests. T…

This study is a registry that will follow 500 people with primary biliary cholangitis (PBC) in Austria. Researchers will collect medical data and optional blood or liver samples to learn how the disease progresses and what complications arise. No new treatment is being tested; th…

This early-stage study is recruiting 44 adults aged 18 to 80, including both healthy people and those with liver problems. All participants will take a single tablet of the drug BI 3000202. Researchers will measure how the drug moves through the body and check for side effects ov…

This study enrolls adults with known or suspected endocrine (hormone gland) disorders, such as diabetes or thyroid disease, to help researchers learn more about these conditions. Participants will undergo medical exams, blood and imaging tests, and possibly genetic testing. The m…

This early-stage study is testing how the drug radiprodil behaves in people with mild, moderate, or severe liver problems compared to healthy adults. About 40 participants will receive a single dose and be monitored for about a week. The goal is to see if liver impairment affects…

This study is looking for new blood markers that could show how much scarring (fibrosis) is in the liver of people with chronic liver disease. Researchers will compare these markers to current tests like FibroScan and liver biopsy. The goal is to find a more accurate and less inv…

This early-stage study is testing an investigational drug called PF-08653944 in 26 adults, some with healthy livers and others with mild to severe liver impairment. Researchers want to see how liver function affects the way the body processes the drug and whether it is safe. Part…

This study looks at how the body handles a single dose of the drug vepdegestrant in people with moderate to severe liver problems compared to healthy people. About 24 adults (ages 18-70) will take one pill and stay at the clinic for 11 days. The goal is to see if liver function a…

This study will follow 1,200 liver transplant patients in France to understand why some people bleed heavily during surgery while others don't. Researchers will use advanced methods like machine learning to build better prediction tools. The goal is to help doctors manage bleedin…

This study is testing a tool called B-COMPASS that uses a 22-question survey to predict whether people will follow their prescribed treatments. Researchers will enroll 3100 adults with cardiovascular, endocrine, immune, nerve, cancer, or rare diseases across Europe. The goal is t…

This study is using advanced whole-genome sequencing to find hidden genetic causes of cholestatic liver disease in adults whose condition remains unexplained after standard tests. Researchers will compare the DNA of 60 affected adults to a large group of healthy controls. The goa…

This study looks at the gut bacteria of 3000 adults with chronic liver diseases like autoimmune hepatitis and fatty liver. Researchers want to find specific bacteria linked to each disease to better understand how the gut and liver interact. This is an observational study, not a …

This early-stage study is testing a single dose of an experimental drug called EDG-7500 in 32 adults. Some have mild or moderate liver problems, while others have normal liver function. Researchers want to see how the drug moves through the body and if it is safe in people with d…

This study looks at how the drug MK-1084 (calderasib) moves through the body in people with and without liver problems. Researchers will measure drug levels in the blood and check for side effects. About 58 adults will take a single dose and be monitored. The goal is to understan…

This study looks at 3,000 people with primary biliary cholangitis (PBC) to see how their blood levels of alkaline phosphatase (ALP) after treatment relate to their risk of liver complications. The goal is to create a model that predicts who will do well and who might need stronge…

This study is creating a digital tool to help teenagers and young adults (ages 14-20) who have had or are waiting for a liver transplant as they move from pediatric to adult care. The tool helps patients and doctors track medication use and well-being from home, reducing hospital…

This study is creating a large collection of blood, urine, stool, bile, and bile duct cells from up to 9,150 people with cholestatic liver diseases like primary biliary cholangitis and primary sclerosing cholangitis, as well as from healthy volunteers. The samples and medical dat…

This study collects blood and tissue samples from 800 people with chronic liver disease or liver cancer. Researchers will use these samples to create lab models, such as cell clusters and mouse tumors, to study these diseases and test new treatments. The goal is to improve unders…

This study is testing a new single probe for FibroScan, a device that measures liver stiffness to assess disease. Researchers want to see if one probe can work as well as the current two-probe system. About 309 adults with chronic liver disease will take part across France and Ho…

This study is testing whether a simple neck ultrasound can predict dangerous drops in blood pressure after anesthesia in adults with chronic liver disease. Researchers will measure blood flow in the carotid artery before and after anesthesia in 35 patients. If the method works, i…

This study looks at how mild and moderate liver problems change the way the body handles a single dose of the drug tasurgratinib. Researchers will compare 18 people with stable liver impairment to healthy volunteers matched by age, weight, race, and gender. The goal is to underst…

This study looks at whether a special MRI scan that measures muscle health and frailty can predict death or the need for a liver transplant in people with liver disease. Researchers will follow 1,200 patients who are already getting an MRI for routine care. The goal is to see if …

This early-stage study is testing how the drug TS-172 behaves in the bodies of people with mild or moderate liver impairment. Researchers will measure drug levels in the blood to see if liver function affects how the drug is processed. The study involves 24 Japanese adults and is…

This study tracks 1,000 patients undergoing major liver, pancreas, or bile duct surgery to see if the time it takes for their albumin levels to return to normal can predict complications and length of hospital stay. Albumin is a protein that drops after surgery due to inflammatio…

This study looks at how the body handles a single dose of the cancer drug olverembatinib in people with normal vs. impaired liver function. Researchers will measure drug levels and safety in 48 adults. The goal is to understand if liver problems require dose adjustments.

This study looks at how a drug called LY3537031 moves through the body in people with mild, moderate, or severe liver problems compared to healthy volunteers. About 32 adults will receive a single injection under the skin. The goal is to understand how liver function affects drug…

This study aims to identify specific blood markers that can distinguish hepatitis caused by immune checkpoint inhibitors from other types of autoimmune hepatitis. Researchers will collect blood samples and liver tissue from 60 adults receiving immunotherapy. The goal is to improv…

This early-stage study will test a drug called saroglitazar magnesium in 6 adults with moderate liver scarring (cirrhosis) caused by cholestatic liver disease. The main goal is to see how the drug moves through the body and if it is safe when taken every other day. Participants w…

This study looks at the social and economic challenges faced by people with chronic liver disease, like trouble paying for food or housing. Researchers will survey 400 patients and their doctors at Indiana University Health to find out what needs are most common and how patients …

This study looks at medical records from 15,000 people to see how chronic liver diseases (like hepatitis, fatty liver, and cirrhosis) are linked to other health problems. Researchers will track new cases of liver cancer and complications over time. The goal is to better understan…

This study will follow 4,000 people with primary biliary cholangitis (PBC), a chronic autoimmune liver disease, across multiple hospitals in China. Researchers will track survival, need for liver transplant, and common symptoms like fatigue and itching. The goal is to better unde…